#SFHS2608280AOrder of April 10, 2026, regarding the coverage conditions of pharmaceutical specialties with marketing authorization
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
This law updates the list of pharmaceutical products covered by health insurance in France. Two specific drugs by Accord Healthcare France are now eligible for reimbursement, but only for uses approved at the date of this order. This affects healthcare providers and patients using these medications.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Updated the list of reimbursable pharmaceutical products
- Included two drugs from Accord Healthcare France for specific uses
- Coverage is limited to approved therapeutic uses at the order's date
Obligations
What this law requires
Healthcare providers and insurers must cover Micafungine ACC 50mg and 100mg (Accord Healthcare France) only for therapeutic indications listed in the marketing authorization as of April 10, 2026
Deny or refuse reimbursement for Micafungine ACC products when prescribed for off-label indications not included in the marketing authorization dated April 10, 2026
Apply patient cost-sharing (participation de l'assuré) rates determined by UNCAM (Union nationale des caisses d'assurance maladie) for Micafungine ACC reimbursements
Register and maintain Micafungine ACC 50mg (UCD: 34008 900 384 4 7) and 100mg (UCD: 34008 900 384 3 0) on the pharmaceutical reimbursement list under article L. 5126-6 of the Public Health Code
Ensure prescribers verify that prescribed indications for Micafungine ACC match the therapeutic indications authorized in the marketing authorization as of April 10, 2026